Home Companies Catalysts Deep Dives
Fintepla fenfluramine APPROVED
Drug Profile
ModalitySmall molecule
RouteOral
Therapy AreaNeurology
Launch2020-06-25
US LOE2036-06-01
Peak Sales Est$800M
Formulations[{"id":"fintepla-oral","doses":"2.2mg/mL","route":"PO","device":"Oral solution","setting":"PATIENT_S
Companies
UCB (ORIGINATOR)100%
Mechanism: Serotonin receptor agonist
Expert: Activates serotonin receptors to reduce seizure activity
Everyday: Activates serotonin receptors to reduce seizure activity
Targets: ["5-HT"]
Revenue History
PeriodRevenue ($M)
2023$256M
2024$342M
Q1 2025$98M
Programs (3)
IndicationStageKey StudyRegional Status
Dravet syndromeAPPROVEDStudy 1 & 2[{"stage":"APPROVED","region":"US","approval_date":"2020-06"},{"stage":"APPROVED
Lennox-Gastaut syndromeAPPROVEDStudy 1501[{"stage":"APPROVED","region":"US","approval_date":"2022-03"}]
CDKL5 deficiency disorderFILEDPhase 3[]
Upcoming Catalysts (1)
Fintepla - Commercial Updates 2026
Notes
Fenfluramine oral solution for Dravet syndrome and Lennox-Gastaut syndrome seizures. Repurposed serotonin-modulating agent with unique mechanism distinct from other anticonvulsants; requires REMS due to cardiac valve monitoring.
Data from Supabase · Updated 2026-03-24